Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05270200
Other study ID # AZA+Chidamide
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date February 1, 2022
Est. completion date July 1, 2024

Study information

Verified date December 2021
Source Zhujiang Hospital
Contact Rui Huang, Doctor
Phone +8615918528317
Email Rachelchn@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical research study is to learn if azacitidine combined with Chidamide will help to control the disease in patients with high-risk AML after an allogeneic stem cell transplant. The safety of this combination will also be studied.


Description:

The Study Drug: Azacitidine is designed to block certain genes in cancer cells whose job is to stop the function of the tumor-fighting genes. By blocking the "bad" genes, the tumor-fighting genes may be able to work better. Chidamide exhibits potent inhibitory effect on cell viability of MDS and AML cells, and the possible mechanism may lie in the downregulation of JAK2/STAT3 signaling through SOCS3 upregulation. Study Group: If you are found to be eligible to take part in this study,you will receive azacitidine and chidamide. Study Drug Administration: You will recieve six courses of azacitidine through a needle under your skin on Days 1-5.Each course is 28 days long.At the same time you will recieve oral chidamide per day for no more than 2 years. The treatment will start after 60 days post-transplantation and your neutrophil count is of 1.5 × 10⁹ cells per L or higher and non-transfused platelets is of 80 × 10⁹ per L or higher. The treatment would stop if neutrophil count is less than 0.5 × 10⁹ cells per L or platelets is less than 20 × 10⁹ per L.And it would also stop when grade 3/4 non-hematological adverse events happened. Study Visit: You may come back for study visits every month in a year when the treatment start. Blood and urine will be drawn for routine tests every month. At 1,2,3,4,5,6,9 and 12 months,You will have a bone marrow aspiration to check the status of the disease. You will have a electrocardiiogram test every 3 months to check the heart function. Length of Study: You will be on study treatment for up to 1 year.You will be taken off study early if you experience intolerable side effects or the disease gets worse. End-of-Treatment Visit: If you complete the planned treatment with azacitidine and chidamide, you will have an end-of-treatment visit: Blood and urine will be drawn for routine tests. You will have a bone marrow aspiration to check the status of the disease. You will have a electrocardiiogram test every 3 months to check the heart function. This is an investigational study. Azacitidine and chidamide are FDA approved and are commercially available for the treatment of acute leukemia.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date July 1, 2024
Est. primary completion date February 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - 1.Age 18 to 60 years old,both male and female - 2.Be able to understand and sign informed consent - 3.Patients with a diagnosis of AML not M3 according to the 2016 World Health Organization (WHO) Acute Myeloid Leukemia Classification and Diagnostic - 4.Patients have AML with poor genetic abnormalities,primary refractory AML,relapsed AML or secondary AML - 5.Patients with an ECOG performance status 0,1,2 or 3 - 6.Expected survival time = 3 months - 7.Non-hematological toxicity related to transplantation does not exceed Grade 2 - 8.Laboratory indicators meet the following standards: 1. 7 days before the first day of the first course of treatment, bilirubin, ALT and AST were all less than 3 times the upper limit of normal. 2. Measure twice within 7 days before the first day of the first course of treatment, at least 2 days apart, the neutrophil count are greater than 1.5×10/L and without G-CSF treatment. 3. Measure twice within 7 days before the first day of the first course of treatment, at least 2 days apart, platelet count greater than 80×10/L and without platelet transfusion. 4. Serum creatinine clearance rate is greater than 30ml/min. Exclusion Criteria: - 1.Uncontrollable active infection - 2.Patients with active hepatitis B or C or HIV infection before enrollment - 3.Have a grade III-IV graft-versus-host disease

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Azacitidine
Patients will recieve six courses of azacitidine 100mg through a needle under skin on Days 1-5.Each course is 28 days long.
Chidamide
Patients will recieve oral chidamide 5mg per day for no more than 2 years.

Locations

Country Name City State
China Nanfang Hospital of Southern Medical University Guanzhou Guandong

Sponsors (1)

Lead Sponsor Collaborator
Zhujiang Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Paticipants With Adverse Events as a Measure of Safety Safety were measured with respect to:
Safety measurements
Incidence of adverse events
From the day of stem cell transplantation to one year after stem cell transplantation
Primary One year cumulative incidence of relapse Leukemia relapse base on morphoogy criterion From the day of stem cell transplantation to one year after stem cell transplantation
Secondary Relapes-free Survival(RFS) The time that a participant survives without relapes of the disease From the day of stem cell transplantation to one year after stem cell transplantation
Secondary Overall survival(OS) The time that a participant survives without death From the day of stem cell transplantation to one year after stem cell transplantation
Secondary The cumulative Incidence rate of GVHD acute GVHD and chronic GVHD diagnosis based on MIH criterion From the day of stem cell transplantation to one year after stem cell transplantation
See also
  Status Clinical Trial Phase
Recruiting NCT05319587 - Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML) Phase 1/Phase 2
Active, not recruiting NCT04090736 - Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy Phase 3
Completed NCT01617226 - Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS Phase 2
Terminated NCT00916045 - Pilot Study of Unrelated Cord Blood Transplantation Phase 2
Terminated NCT00957580 - Trial of Pimasertib in Hematological Malignancies Phase 2
Completed NCT00640796 - Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors Phase 1
Completed NCT00458250 - Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1H Phase 1
Active, not recruiting NCT05424380 - A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS Phase 1
Completed NCT01690624 - BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients in Complete Remission With High Risk to Relapse Phase 1
Recruiting NCT05471700 - Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients Phase 1/Phase 2
Not yet recruiting NCT05016063 - Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia Early Phase 1
Not yet recruiting NCT04450784 - ObServatory Children Acute RElated Therapy Leukemia
Recruiting NCT04265963 - CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia Phase 1/Phase 2
Terminated NCT04968860 - Oral Health Condition and Quality of Life in Children With Leukemia
Recruiting NCT03793517 - Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT Phase 2/Phase 3
Terminated NCT02841540 - A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes Phase 1
Recruiting NCT05453903 - A Study of JNJ-75276617 in Combination With Acute Myeloid Leukemia (AML) Directed Therapies Phase 1
Completed NCT03720366 - A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients Phase 1
Withdrawn NCT04230564 - Acute Myeloid Leukemia Real World Treatment Patterns
Terminated NCT03761069 - Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias Phase 1